Older Adult Perspectives on Statin Continuation and Discontinuation in Primary Cardiovascular Disease Prevention: A Mixed-Methods Study
Laureline Brunner,Blandine Mooser,Anne Spinewine,Nicolas Rodondi,Carole Elodie Aubert
DOI: https://doi.org/10.2147/ppa.s432448
2024-01-03
Patient Preference and Adherence
Abstract:Laureline Brunner, 1 Blandine Mooser, 1, 2 Anne Spinewine, 3, 4 Nicolas Rodondi, 1, 2 Carole Elodie Aubert 1, 2 1 Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland; 2 Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; 3 Université catholique de Louvain, Louvain Drug Research Institute, Clinical Pharmacy Research Group, Brussels, Belgium; Department of Pharmacy, Centre Hospitalier Universitaire (CHU) UCL Namur, Yvoir, Belgium; 4 Clinical Pharmacy Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium Correspondence: Carole Elodie Aubert, Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Anna-von-Krauchthal Weg 7, Bern, CH-3010, Switzerland, Tel +41 31 632 03 98, Email Background and Purpose: Evidence for statin use for primary cardiovascular disease prevention in older adults is limited. When evidence on risk-benefit profile of a medication is uncertain, using it or not becomes a preference-sensitive decision. We aimed to assess and explore patient perspectives on continuation and discontinuation of statins used for primary cardiovascular prevention in older adults. Patients and Methods: We used a convergent mixed-methods design, conducting in parallel a survey among 47 patients and three focus groups (FGs) with 14 patients total. We recruited patients aged ≥ 65 years and taking a statin for primary cardiovascular prevention. The survey and FGs aimed to assess and explore patient experiences of statin use, and views on statin continuation and discontinuation, including patient decision-making. Quantitative and qualitative data were first analyzed separately – descriptive statistics for quantitative data and thematic analysis for qualitative data – and then integrated to create metainferences, using joint displays. Results: Forty-one percent of patients (N=19) were reluctant to discontinue the statin, whereas 22% (N=10) were willing to try discontinuing it. A reason to continue the statin was its perceived necessity, while self-estimated low cardiovascular risk and wish to reduce medication burden were given as reasons to discontinue it. Lack of expertise assumed by the patients to decide about statin continuation or discontinuation, uncertainty about statin indication, and fear of having a cardiovascular event after discontinuation made many patients uncertain about deciding to continue or discontinue the statin. In this context, 70% (N=33) would rather have their physician choose for them, and 94% (N=44) would continue taking the statin for as long as their physician told them to do so. Conclusion: This study highlights factors that influence patient willingness to continue or discontinue statins, patient uncertainty about statin continuation or discontinuation, and the important role physicians play in the decision-making process. Keywords: barriers, facilitators, primary care providers, statins Statins are among the most frequently prescribed chronic medications in older adults, and their prescription rates have increased in recent years. 1–3 While benefits of statins for secondary cardiovascular disease (CVD) prevention are well demonstrated, 4 evidence for their benefits in primary CVD prevention is weaker, particularly among older adults. 5,6 Only 8% of participants enrolled in statin trials on primary CVD prevention were aged 75 years or older, and no statistically significant benefit was found for adults older than 70 years of age. 6,7 Despite this lack of evidence, statins are more frequently prescribed for primary CVD prevention in older rather than in younger adults. 8 Statins are also associated with adverse drug events (ADEs), such as muscle pain, myopathy, acute renal failure, or liver dysfunction, which might decrease quality of life. 9 When evidence is uncertain about the benefits of a medication, to continue taking it or not becomes a preference-sensitive decision. 10,11 As such, the American Heart Association recommends accounting for patient priorities of care, and using shared decision-making between patients and clinicians when addressing statin use for primary CVD prevention. 5,12 However, little is known about older patient perspectives regarding statin continuation and discontinuation when used for primary CVD prevention. A previous qualitative study on older patient perspectives on deprescribing showed that older adults taking a statin in primary CVD prevention feared a cardiovascular event if they di -Abstract Truncated-
medicine, general & internal